Nijhawan Pardeep 4

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 11,168 restricted share units (RSUs) on 2026-02-02. The RSUs vested in full upon grant and were reported as acquired at $0.00, resulting in no cash payment by the reporting person.
• Transaction type: Award/Grant (code A). Reported acquisition value: $0.

Key Details

• Transaction date: 2026-02-02; Price per share reported: $0.00; Shares acquired: 11,168 RSUs.
• Filing date/accession: Report filed 2026-02-02 (appears timely; no late filing indicated).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: These were RSUs granted under the Issuer's 2019 Equity Incentive Compensation Plan and vested in full upon grant.
  • F2 & F3: Some reported shares are held by entities/trusts wholly owned or co-trusteed by the reporting person; Nijhawan disclaims beneficial ownership except to the extent of his pecuniary interest.

Context

• RSU grants that vest immediately are a form of compensation, not an open-market purchase or sale, and do not necessarily indicate the insider is buying or selling based on company outlook.
• The disclaimers about entity/trust ownership mean some shares appear in this filing for reporting purposes but may be owned by related entities; that does not change the nature of the award.